{"id":45344,"date":"2022-06-22T12:01:43","date_gmt":"2022-06-22T10:01:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\/"},"modified":"2022-06-22T12:01:43","modified_gmt":"2022-06-22T10:01:43","slug":"global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\/","title":{"rendered":"Global Arthritis Monoclonal Antibodies Markets 2022-2026 &amp; 2031: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5553731\/arthritis-monoclonal-antibodies-global-market?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=7hvzfs&amp;utm_campaign=1716600+-+Global+Arthritis+Monoclonal+Antibodies+Markets+2022-2026+%26+2031%3A+Remicade%2C+Humira%2C+Enbrel%2C+Rituxan%2C+Orencia%2C+Actemra%2C+Simponi%2C+Cimzia%2C+Remsima&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Arthritis Monoclonal Antibodies Global Market Report 2022: By Drug, By Application, By End-Use&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220622005513\/en\/1493752\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220622005513\/en\/1493752\/21\/logo.jpg\"><\/a><\/p>\n<p>\nArthritis Monoclonal Antibodies Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global arthritis monoclonal antibodies (mab&#8217;s) market.\n<\/p>\n<p>\nThis report focuses on arthritis monoclonal antibodies (mab&#8217;s) market which is experiencing strong growth. The report gives a guide to the arthritis monoclonal antibodies (mab&#8217;s) market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.\n<\/p>\n<p>\nThe report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market&#8217;s historic and forecast market growth by geography. It places the market within the context of the wider arthritis monoclonal antibodies (mab&#8217;s) market, and compares it with other markets.\n<\/p>\n<p>\nWhere is the largest and fastest growing market for the arthritis monoclonal antibodies (mab&#8217;s)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Arthritis Monoclonal Antibodies (mab&#8217;s) market global report answers all these questions and many more.\n<\/p>\n<p>\nThe countries covered in the arthritis monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.\n<\/p>\n<p>\n<strong>Report Scope<\/strong>\n<\/p>\n<ul>\n<li>\nThe market characteristics section of the report defines and explains the market\n<\/li>\n<li>\nThe market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth\n<\/li>\n<li>\nMarket segmentations break down market into sub markets\n<\/li>\n<li>\nThe regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets\n<\/li>\n<li>\nCompetitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified\n<\/li>\n<li>\nThe trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers\n<\/li>\n<li>\nThe arthritis monoclonal antibodies (mab&#8217;s) market section of the report gives context. It compares the arthritis monoclonal antibodies (mab&#8217;s) market with other segments of the arthritis monoclonal antibodies (mab&#8217;s) market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, arthritis monoclonal antibodies (mab&#8217;s) indicators comparison\n<\/li>\n<\/ul>\n<p>\n<strong>Markets Covered:<\/strong>\n<\/p>\n<ul>\n<li>\nBy Drug: Remicade; Humira; Enbrel; Rituxan; Orencia; Actemra; Simponi; Cimzia; Remsima\n<\/li>\n<li>\nBy Application: Rheumatoid Arthritis; Osteoarthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Fibromyalgia; Others\n<\/li>\n<li>\nBy End-Use: Hopitals; Research Institutes; Others\n<\/li>\n<\/ul>\n<p>\n<strong>Major Companies Mentioned:<\/strong>\n<\/p>\n<ul>\n<li>\nJohnson &amp; Johnson\n<\/li>\n<li>\nRoche\n<\/li>\n<li>\nNovartis\n<\/li>\n<li>\nPfizer Inc\n<\/li>\n<li>\nAbbVie Inc\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>1. Executive Summary<\/strong>\n<\/p>\n<p>\n<strong>2. Arthritis Monoclonal Antibodies Market Characteristics<\/strong>\n<\/p>\n<p>\n<strong>3. Arthritis Monoclonal Antibodies Market Trends And Strategies<\/strong>\n<\/p>\n<p>\n<strong>4. Impact Of COVID-19 On Arthritis Monoclonal Antibodies<\/strong>\n<\/p>\n<p>\n<strong>5. Arthritis Monoclonal Antibodies Market Size And Growth<\/strong>\n<\/p>\n<p>\n5.1. Global Arthritis Monoclonal Antibodies Historic Market, 2016-2021, $ Billion\n<\/p>\n<p>\n5.1.1. Drivers Of The Market\n<\/p>\n<p>\n5.1.2. Restraints On The Market\n<\/p>\n<p>\n5.2. Global Arthritis Monoclonal Antibodies Forecast Market, 2021-2026F, 2031F, $ Billion\n<\/p>\n<p>\n5.2.1. Drivers Of The Market\n<\/p>\n<p>\n5.2.2. Restraints On the Market\n<\/p>\n<p>\n<strong>6. Arthritis Monoclonal Antibodies Market Segmentation<\/strong>\n<\/p>\n<p>\n6.1. Global Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion\n<\/p>\n<ul>\n<li>\nRemicade\n<\/li>\n<li>\nHumira\n<\/li>\n<li>\nEnbrel\n<\/li>\n<li>\nRituxan\n<\/li>\n<li>\nOrencia\n<\/li>\n<li>\nActemra\n<\/li>\n<li>\nSimponi\n<\/li>\n<li>\nCimzia\n<\/li>\n<li>\nRemsima\n<\/li>\n<\/ul>\n<p>\n6.2. Global Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion\n<\/p>\n<ul>\n<li>\nRheumatoid Arthritis\n<\/li>\n<li>\nOsteoarthritis\n<\/li>\n<li>\nPsoriatic Arthritis\n<\/li>\n<li>\nAnkylosing Spondylitis\n<\/li>\n<li>\nFibromyalgia\n<\/li>\n<li>\nOthers\n<\/li>\n<\/ul>\n<p>\n6.3. Global Arthritis Monoclonal Antibodies Market, Segmentation By End-use, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion\n<\/p>\n<ul>\n<li>\nHopitals\n<\/li>\n<li>\nResearch Institutes\n<\/li>\n<li>\nOthers\n<\/li>\n<\/ul>\n<p>\n<strong>7. Arthritis Monoclonal Antibodies Market Regional And Country Analysis<\/strong>\n<\/p>\n<p>\n7.1. Global Arthritis Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion\n<\/p>\n<p>\n7.2. Global Arthritis Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion\n<\/p>\n<p>\n<strong>Companies Mentioned<\/strong>\n<\/p>\n<ul>\n<li>\nJohnson &amp; Johnson\n<\/li>\n<li>\nRoche\n<\/li>\n<li>\nNovartis\n<\/li>\n<li>\nPfizer inc.\n<\/li>\n<li>\nAbbVie inc.\n<\/li>\n<li>\nAmgen inc.\n<\/li>\n<li>\nGenentech\n<\/li>\n<li>\nGSK\n<\/li>\n<li>\nAstraZeneca plc.\n<\/li>\n<li>\nMylan N.V.\n<\/li>\n<li>\nBristol Myers Squibb\n<\/li>\n<li>\nEli Lily and Company\n<\/li>\n<li>\nThermofischer Scientific\n<\/li>\n<li>\nSanofi\n<\/li>\n<li>\nNovo Nordisk A\/S\n<\/li>\n<li>\nDaiichi Sankyo Company ltd.\n<\/li>\n<li>\nSeattle genetics\n<\/li>\n<li>\nTeva pharmaceutical industries\n<\/li>\n<li>\nShanghi Junsi bioscience ltd.\n<\/li>\n<li>\nGenScript\n<\/li>\n<li>\nSigma-Aldrich Co. LLC\n<\/li>\n<li>\nAbGenomics\n<\/li>\n<li>\nADC Therapeutics\n<\/li>\n<li>\nAgensys\n<\/li>\n<li>\nAlexion Pharmaceuticals\n<\/li>\n<li>\nALMAC Group\n<\/li>\n<li>\nAmbrx\n<\/li>\n<li>\nAstellas Pharma\n<\/li>\n<li>\nCelgene\n<\/li>\n<li>\nCelldex Therapeutics\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5553731\/arthritis-monoclonal-antibodies-global-market?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=7hvzfs&amp;utm_campaign=1716600+-+Global+Arthritis+Monoclonal+Antibodies+Markets+2022-2026+%26+2031%3A+Remicade%2C+Humira%2C+Enbrel%2C+Rituxan%2C+Orencia%2C+Actemra%2C+Simponi%2C+Cimzia%2C+Remsima&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/tr4shj<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#97;&#x69;l&#116;&#x6f;&#x3a;p&#114;&#x65;&#x73;s&#64;&#x72;&#x65;s&#101;&#x61;&#x72;c&#104;&#x61;&#x6e;d&#109;&#x61;r&#107;&#101;&#x74;s&#46;&#x63;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">p&#114;&#x65;&#x73;s&#64;&#114;&#x65;&#x73;e&#97;&#114;&#x63;&#x68;a&#110;&#x64;&#x6d;&#x61;r&#107;&#x65;&#x74;s&#46;&#99;&#x6f;&#x6d;<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Arthritis Monoclonal Antibodies Global Market Report 2022: By Drug, By Application, By End-Use&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. Arthritis Monoclonal Antibodies Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global arthritis monoclonal antibodies (mab&#8217;s) market. This report focuses on &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45344","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Global Arthritis Monoclonal Antibodies Markets 2022-2026 &amp; 2031: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global Arthritis Monoclonal Antibodies Markets 2022-2026 &amp; 2031: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Arthritis Monoclonal Antibodies Global Market Report 2022: By Drug, By Application, By End-Use&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. Arthritis Monoclonal Antibodies Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global arthritis monoclonal antibodies (mab&#8217;s) market. This report focuses on ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-22T10:01:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220622005513\/en\/1493752\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Global Arthritis Monoclonal Antibodies Markets 2022-2026 &amp; 2031: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-06-22T10:01:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\\\/\"},\"wordCount\":812,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220622005513\\\/en\\\/1493752\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\\\/\",\"name\":\"Global Arthritis Monoclonal Antibodies Markets 2022-2026 &amp; 2031: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220622005513\\\/en\\\/1493752\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-06-22T10:01:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220622005513\\\/en\\\/1493752\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220622005513\\\/en\\\/1493752\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Global Arthritis Monoclonal Antibodies Markets 2022-2026 &amp; 2031: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Global Arthritis Monoclonal Antibodies Markets 2022-2026 &amp; 2031: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Global Arthritis Monoclonal Antibodies Markets 2022-2026 &amp; 2031: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Arthritis Monoclonal Antibodies Global Market Report 2022: By Drug, By Application, By End-Use&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. Arthritis Monoclonal Antibodies Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global arthritis monoclonal antibodies (mab&#8217;s) market. This report focuses on ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-22T10:01:43+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220622005513\/en\/1493752\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Global Arthritis Monoclonal Antibodies Markets 2022-2026 &amp; 2031: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima &#8211; ResearchAndMarkets.com","datePublished":"2022-06-22T10:01:43+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\/"},"wordCount":812,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220622005513\/en\/1493752\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\/","name":"Global Arthritis Monoclonal Antibodies Markets 2022-2026 &amp; 2031: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220622005513\/en\/1493752\/21\/logo.jpg","datePublished":"2022-06-22T10:01:43+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220622005513\/en\/1493752\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220622005513\/en\/1493752\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/global-arthritis-monoclonal-antibodies-markets-2022-2026-2031-remicade-humira-enbrel-rituxan-orencia-actemra-simponi-cimzia-remsima-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Global Arthritis Monoclonal Antibodies Markets 2022-2026 &amp; 2031: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45344","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45344"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45344\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45344"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45344"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45344"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}